While the EVUSHELD outcome does indicate a stronger move to apply the institutionalised decision-making framework, the transition does pose a challenge for decision-makers who will need to ensure the consistent and equitable consideration of vaccines and therapies for COVID-19.
Outcome highlights the challenge of delivering consistent approach
October 17, 2022 Latest NewsBioPharmaNews of the DayComment
Latest Video
New Stories
-
Moderna taps Salesforce to unify global commercial operations
April 30, 2026 - - Latest News -
How do we know the HTA institution loves patients? Because they use a love heart emoji
April 30, 2026 - - Latest News -
Australian company secures capital raise to advance amsulostat trials and strengthen pipeline
April 29, 2026 - - Latest News -
Australia urged to strengthen sunscreen literacy and label clarity
April 29, 2026 - -
'Let me once again explain why we must close the gap for people with cystic fibrosis–related diabetes'
April 29, 2026 - - Latest News -
We need to say it again, just in case, that this advice is about ministerial choices and not conditions
April 29, 2026 - - Latest News -
Families welcome cancer drug progress but remain cautious over timely access
April 28, 2026 - - Latest News
